Harinarayan Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 29-06-2024
- Paid Up Capital ₹ 3.50 Cr
as on 29-06-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 50.00 Cr
as on 29-06-2024
- Revenue -99.25%
(FY 2021)
- Profit -99.67%
(FY 2021)
- Ebitda -99.93%
(FY 2021)
- Net Worth 0.36%
(FY 2021)
- Total Assets -4.60%
(FY 2021)
About Harinarayan Lifesciences
The Corporate was formerly known as Krsna Lifesciences Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company has closed loans amounting to ₹50.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Narayan Chighlikar and Shubhangi Chighalikar serve as directors at the Company.
- CIN/LLPIN
U74900PN2010PTC138080
- Company No.
138080
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Harinarayan Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayan Chighlikar  | Director | 29-Dec-2011 | Current |
| Shubhangi Chighalikar | Director | 20-Mar-2018 | Current |
Financial Performance and Corporate Structure Insights of Harinarayan Lifesciences.
Harinarayan Lifesciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 99.25% decrease. The company also saw a substantial fall in profitability, with a 99.67% decrease in profit. The company's net worth moved up by a moderate rise of 0.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harinarayan Lifesciences?
In 2021, Harinarayan Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Janata Sahakari Bank Ltd Pune Creation Date: 05 Dec 2012 | ₹25.00 Cr | Satisfied |
Janata Sahakari Bank Ltd Pune Creation Date: 27 Nov 2012 | ₹25.00 Cr | Satisfied |
How Many Employees Work at Harinarayan Lifesciences?
Unlock and access historical data on people associated with Harinarayan Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harinarayan Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harinarayan Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
